SCHEMBL7218667

SCHEMBL7218667

O=C(O)/C(=C/c1ccccc1Cl)c1ccccc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C1 Q04828 3/20 0.58
KMT2A Q03164 5/20 0.57
MEN1 O00255 4/20 0.57
ALDH1A1 P00352 4/20 0.57
LMNA P02545 2/20 0.57
HPGD P15428 1/20 0.57
NPSR1 Q6W5P4 1/20 0.57
POLB P06746 2/20 0.47
RECQL P46063 1/20 0.47
AKR1C2 P52895 2/20 0.46
AKR1C3 P42330 1/20 0.46
TRPA1 O75762 1/20 0.46
CYP1A2 P05177 1/20 0.46
MAPK1 P28482 1/20 0.46
BLM P54132 1/20 0.46
PMP22 Q01453 1/20 0.46
PTGS2 P35354 1/20 0.45
NPC1 O15118 1/20 0.42
MAPT P10636 1/20 0.42
MAOB P27338 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7666255 1.00 AKR1C1 (0.58) AKR1C1KMT2AMEN1ALDH1A1LMNA
SCHEMBL9239140 0.88 ALDH1A1 (0.51) AKR1C1KMT2AMEN1ALDH1A1LMNA
SCHEMBL8805362 0.86 KMT2A (0.58) AKR1C1KMT2AMEN1ALDH1A1LMNA
SCHEMBL8805358 0.86 KMT2A (0.58) AKR1C1KMT2AMEN1ALDH1A1LMNA
SCHEMBL8648115 0.85 ALDH1A1 (0.60) AKR1C1KMT2AMEN1ALDH1A1LMNA
SCHEMBL8648112 0.85 ALDH1A1 (0.60) AKR1C1KMT2AMEN1ALDH1A1LMNA
SCHEMBL7666908 0.82 LMNA (0.54) KMT2AMEN1ALDH1A1LMNAHPGD
SCHEMBL7666912 0.82 LMNA (0.54) KMT2AMEN1ALDH1A1LMNAHPGD
SCHEMBL8644175 0.79 KMT2A (0.43) KMT2AMEN1ALDH1A1LMNAHPGD
SCHEMBL8644173 0.79 KMT2A (0.43) KMT2AMEN1ALDH1A1LMNAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6624197-B1 Styrene administered orally to decrease blood glucose levels in rats. The glucose tolerance in insulin resistant rats is also shown, as well as lowering of triglyceride levels in serum insulin resistant, hyperinsulinemic and CALYX THERAPEUTICS, INC. 2003-09-23 US disclosed
US-6492531-B1 THE INVENTION CONCERNS CHOLECYSTOKININ (CCK) ANTAGONISTS USEFUL IN THE TREATMENT OF COGNITIVE DISORDERS. ESPECIALLY USEFUL ARE CCK.SUB.B ANTAGONISTS SUCH AS CI-988. WARNER-LAMBERT COMPANY 2002-12-10 US disclosed
EP-0729752-A2 Central cholecystokinin antagonists having pharmaceutical activity MERCK SHARP & DOHME LTD. (GB) 1996-09-04 EP disclosed
WO-1993012817-A1 THERAPEUTIC COMBINATIONS USEFUL IN THE TREATMENT OF GASTROESOPHAGEAL REFLUX DISEASE WARNER-LAMBERT COMPANY (US) 1993-07-08 WO disclosed